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Objective To investigate if Chlamydia pneumoniae and/or Helicobacter pylori seropositiv-
ity is associated with elevated levels of soluble endothelial cell adhesion molecules
(sCAMs) as markers of atherosclerotic activity.
Methods Immunoglobulin A (IgA) and IgG antibodies to the two bacteria, soluble
intercellular cell adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion mole-
cule-1 (sVCAM-1) and E-selectin were measured in coronary heart disease (CHD)
patients (n¼ 193) and age- and sex-matched controls (n¼ 193). Two different serological
methods were used for the detection of Chlamydia antibodies: Labsystems microimmu-
noﬂuorescence to detect species-speciﬁc C. pneumoniae antibodies and Medac’s recom-
binant enzyme-linked immunosorbent assay to detect genus-speciﬁc lipopolysaccharide
antibodies.
Results The concentrations of sICAM-1 and E-selectin were higher in CHDpatients with
positive vs. negative Chlamydia lipopolysaccharide IgA (P¼ 0.044 for both). H. pylori
antibodies alone did not predict raised levels of sCAMs, but in CHD patients sICAM-1
was increasedwith IgA seropositivity to both bacteria compared to double seronegativity
(P¼ 0.034). Concentrations of sVCAM-1 were elevated in CHD patients with double IgA
seropositivity compared to those with Chlamydia lipopolysaccharide IgA seropositivity
alone (P¼ 0.018).
Conclusion Our results may indicate that C. pneumoniae contributes to increased inﬂam-
mation in CHD, and that this contribution is even more pronounced when present in
combination with H. pylori IgA antibodies.
Keywords Chlamydia pneumoniae, Helicobacter pylori, vascular cell adhesion molecule,
intercellular cell adhesion molecule, E-selectin, coronary heart disease,
inﬂammation
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INTRODUCTION
Atherosclerosis is now generally accepted as an
inﬂammatory disorder in the arterial wall [1].
Early stages in the development of atherosclerosis
are characterized by subendothelial lipid accumu-
lation and leucocyte adhesion to the endothelium
resulting in inﬁltration of macrophages and T
lymphocytes into the arterial intima [1]. Endothe-
lial cell adhesion molecules play a central role in
the adherence of leucocytes, and the activated
endothelium has been shown to express various
adhesion molecules such as vascular cell adhesion
molecule-1 (VCAM-1), intercellular adhesion
molecule-1 (ICAM-1) and E-selectin [2,3]. Elevated
levels of soluble adhesion molecules (sCAMs)
have also been found in patients with coronary
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heart disease (CHD) and peripheral atherosclero-
sis [4–7] compared to healthy individuals.
The possible relationship between microbial
agents and atherosclerosis remains controversial.
Most seroepidemiological studies published have
shown a higher prevalence of antibodies to Chla-
mydia pneumoniae and/orHelicobacter pylori among
patients with CHD compared to healthy indivi-
duals [8–10], but there are also studies which do
not show this [11,12]. There is a substantial amount
of evidence for the presence of C. pneumoniae
within atherosclerotic plaques [13–15], but its
pathogenetic role is still uncertain.
Presuming that micro-organisms contribute to
atherosclerosis, local as well as systemic pathways
may be operative. Experimental studies have
shown that C. pneumoniae can maintain infection
in endothelial cells, macrophages and smooth
muscle cells and induce foam cell formation [16–
18]. Infected human aortic endothelial cells have
been shown in vitro to express increased amounts
of ICAM-1, VCAM-1 and E-selectin on the surface
[19,20]. It is not settled, however, settled whether
in vivo infection with C. pneumoniae leads to an
increase in sCAMs in humans.
Although there have been a few positive reports
[21], most investigators have failed to demonstrate
the presence ofH. pylori in the arterial wall [22,23].
However, this micro-organism’s tendency to pro-
duce chronic infection and inﬂammation is well
known from gastroenterology, and there is still a
possibility of systemic inﬂuence causing vascular
inﬂammation.
The aim of the present study was to investigate
if seropositivity to C. pneumoniae and/or H. pylori
is associated with increased levels of markers of
vascular inﬂammation, possibly indicating that
infection with these microbes contributes to the
process of atherosclerosis. Levels of sVCAM-1,
sICAM-1 and E-selectin weremeasured asmarkers
of endothelial inﬂammation and were compared
between seropositive and seronegative individuals.
Both CHD patients and matched healthy controls
were included and investigated separately. In the
absence of a reference standard for measurements
of C. pneumoniae antibodies, and knowing that the
choice of method might inﬂuence the serological
results [24], we included two fundamentally dif-
ferent methods for C. pneumoniae serology, one
detecting species-speciﬁc antibodies [Labsystems
microimmunoﬂuorescence (MIF)] and another
method detecting genus-speciﬁc lipopolysacchar-
ide (LPS) antibodies [Medac’s recombinant
enzyme-linked immunosorbent assay (rELISA)].
METHODS
Study population
The study population comprised 193 patients with
documented CHD and 193 age- and sex-matched
healthy controls from the county of Vestfold, Nor-
way. The CHD patients were included at a median
of 16 days after an acute myocardial infarction
(AMI) (n¼ 74), percutaneous transluminal coron-
ary angioplasty (n¼ 38), or coronary artery bypass
surgery (n¼ 50). AMI was deﬁned as typical clin-
ical symptoms (chest pain and/or dyspnoea)
accompanied by typical electrocardiographic ﬁnd-
ings [development of pathological Q waves or ST
deviations (non-Q)] and signiﬁcant increase of
cardiac enzymes [creatine kinase (CK) >250U/
L, and/or creatine kinase myocardial-speciﬁc iso-
zyme CKMB >10 mg/L; World Health Organiza-
tion criteria]. In addition, 31 patients in a chronic
stage of CHD, with more than a 3month lapse of
time since their last acute event, were included. Of
the CHD patients, 135 (70%) had a previous myo-
cardial infarction in their history. None of the
patients had severe heart failure.
Four hundred healthy controls were recruited
from four working sites in Vestfold county, and for
each CHD patient included in the study, one age-
and sex-matched control subject was drawn from
this control pool. This apparently healthy indivi-
dual was then included after an interview and a
clinical examination with a near-maximal bicycle
electrocardiogram, if no symptoms or clinical evi-
dence of atherosclerotic disease were present. We
also aimed to match educational level, but there
was a somewhat higher proportion of healthy
individuals with academic education in the control
group (43%) than in the CHD group (34%).
The study was approved by the regional ethics
committee, and all patients and controls gave their
informed, written consent to participate. Blood
samples were drawn at inclusion in a fasting con-
dition, and serum was prepared within 1 h and
kept frozen at 708C until analysis.
Laboratory methods
All blood samples were analysed using the follow-
ing methods. Chlamydia pneumoniae MIF immuno-
globulin A (IgA) and IgG (Labsystems, Helsinki,
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Finland) is a species-speciﬁc test where C. pneu-
moniae elementary bodies are used as antigen. All
samples were screened at a titre of 1 : 16, then
evaluated at serial two-fold dilutions up to
1 : 128 for IgA and 1 : 512 for IgG. A positive IgA
test was deﬁned as IgA 32, while a positive IgG
was deﬁned as titre 64. The Chlamydia IgA and
IgG rELISA (Medac, Hamburg, Germany) is a
recombinant enzyme immunoassay for detection
of the genus-speciﬁc LPS antibodies, in which,
according to the manufacturer, seropositivity is
deﬁned as IgA 50 and IgG 100. The Pyloriset
EIA-A III and EIA-G III (Orion Diagnostica, Espoo,
Finland) is an enzyme immunoassay for the detec-
tion and measurement of H. pylori IgA and IgG,
seropositivity is deﬁned as  20 ulml for both.
Adhesion molecules were measured using the
Human soluble ICAM-1 Parameter, the Human
soluble VCAM-1 Parameter, and the Human solu-
ble E-Selectin Parameter (all supplied by R&D
Systems Europe, Abingdon, UK). BecauseMedac’s
rELISA test does not discriminate between the
Chlamydia species, the patients who were either
IgA or IgG positive in Medac’s rELISA test were
also tested by the Medac Chlamydia trachomatis
pELISA IgA and IgG, which detects species-spe-
ciﬁc antibodies to C. trachomatis.
Statistical methods
Results were analyzed statistically using SPSS FOR
WINDOWS, version 9.0. The Pearson w2 test was used
to compare the number of seropositives in the two
study groups. The independent t-test was used
when comparing means of sCAMS between sero-
positive and seronegative individuals. Because
there is no general agreement in the literature
about what cut-off levels should be applied when
performing MIF [25], we also compared seroposi-
tives and seronegatives at one cut-off level above
and one below the chosen limit. To evaluate if H.
pylori and/or C. pneumoniae antibodies were inde-
pendent predictive factors for the sCAMs, seropo-
sitivity was introduced, together with established
coronary risk factors, into a multiple linear regres-
sionmodel. Lipids andbloodpressurewere exclud-
ed as risk factors in the CHD population because of
medication, but were included in multivariate ana-
lysis concerning the healthy controls alone.
In line with suggestions by Rothman [26], to
avoid the chance of discarding biological rationale,
we have not included corrections for multiple
comparisons. In all the statistical analyses a two-
tailed signiﬁcance level <0.05 was regarded as
statistically signiﬁcant.
RESULTS
The baseline characteristics of the two study
groups are given in Table 1. The mean age was
55 years (27–68), and 18% were women. Of the
CHD patients, 176 (91%) were on statin treatment
at the time of sampling and 187 (97%) were on
medication with either beta-blockers, calcium
antagonists or angiotensin-converting enzyme
(ACE) inhibitors. As a consequence these patients
had signiﬁcantly lower levels of blood pressure,
and of total and low-density lipoprotein choles-
terol compared to their matched controls.
The numbers of C. pneumoniae and/or H. pylori
seropositive individuals in the study populations
Table 1 Baseline characteristics in CHD patients vs.
healthy controls
CHD
patients
(n¼ 193)
Healthy
controls
(n¼ 193) P
Diabetes type 2 7.3% 3.6% 0.116
Treated hypertension 37.8% 8.3% <0.001
Medication
statins 91.0% 1.6% <0.001
beta-blockers 94.8% 1.0% <0.001
ACE inhibitors 16.6% 2.1% <0.001
calcium antagonists 7.3% 0.5% 0.001
diuretics 4.7% 1.0% 0.032
warfarin 9.8% 0 <0.001
aspirin 90.7% 0.5% <0.001
Smokers at inclusion 21.8% 25.9% 0.339
Ex-smokers 59.1% 32.1% <0.001
BMI (kg/m2) 27.2 (3.9) 25.8 (3.2) <0.001
Blood pressure
systolic 125 (17) 135 (17) <0.001
diastolic 79 (10) 83 (8) <0.001
Total cholesterol
(mmol/L)
4.76 (0.95) 5.69 (0.96) <0.001
HDL cholesterol
(mmol/L)
0.97 (0.30) 1.39 (0.41) <0.001
Tot chol/HDL 5.29 (1.81) 4.44 (1.52) <0.001
LDL cholesterol
(mmol/L)
3.05 (0.91) 3.72 (0.89) <0.001
Triglycerides
(mmol/L)
1.71 (0.99) 1.26 (0.70) <0.001
For continuous variables mean values (SD) are given.
P gives the two-tailed significance of the difference
between CHD patients and healthy controls. Pearson w2
test was used to compare categorical variables, while an
independent t-test was used to compare continuous
variables between the two study groups.
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are shown in Table 2. A signiﬁcant difference in
Chlamydia LPS IgG (P¼ 0.024) andHelicobacter IgA
seropositivity (P¼ 0.042) was observed between
the CHD patients and the healthy controls. The
difference in Chlamydia LPS IgA between the study
groups was not statistically signiﬁcant at the cut-
off level chosen, but a signiﬁcantly higher propor-
tion of the CHD patients had Chlamydia LPS
IgA> 100 when compared to the healthy controls
(24% in the CHD group vs. 14% among controls,
P¼ 0.014, data not shown). The numbers of C.
pneumoniae MIF IgA and IgG seropositives in the
two study groups were similar whatever cut-off
level was chosen.
The levels of sCAMs were then compared
between C. pneumoniae seropositive and seronega-
tive individuals within each study group. IgA and
IgG serological status was evaluated separately. In
the healthy individuals there was no association
between Chlamydia serology and the levels of
sCAMs, whereas signiﬁcant differences were
observed with Chlamydia LPS IgA serology in
the CHD group, as shown in Table 3. In CHD
patients, Chlamydia LPS IgA antibody at a titre
1 : 50 was signiﬁcantly associated with sICAM-
1 and E-selectin levels (P¼ 0.044 for both). C.
pneumoniae IgA seropositivity measured by MIF
technique or C. pneumoniae IgG seropositivity with
any of the two methods used, did not reveal any
statistically signiﬁcant differences in the inﬂam-
matory markers at any cut-off level. When
Chlamydia LPS IgA seropositivity (50) was intro-
duced into a linear regression model together with
smoking habits, diabetes and body mass index
(BMI) in CHD patients, Chlamydia LPS IgA sero-
positivity was still an independent predictive fac-
tor for sICAM-1 (P¼ 0.011) together with smoking
(P¼ 0.004), while the other factors were non-sig-
niﬁcant. E-selectin in the CHD patients was sig-
niﬁcantly predicted by Chlamydia LPS IgA
seropositivity (P¼ 0.038) and BMI (P¼ 0.032).
Among the LPS-positive CHDpatients, 9%were
C. trachomatis IgA positive, vs. 5% among the
healthy controls, and for IgG the percentages were
21 vs. 18, respectively. These differences were not
statistically signiﬁcant. No signiﬁcant differences
in the sCAMs were observed between C. tracho-
matis-positive and -negative individuals (data not
shown).
C. trachomatis and H. pylori IgA or IgG status
was not associated with any differences in the
measured inﬂammatory markers in either of the
two study groups (data not shown). The mean
value of sICAM-1, however, was signiﬁcantly
higher in the CHD patients with Chlamydia LPS
IgA and H. pylori IgA seropositivity compared to
the patient group that was negative for both
(P¼ 0.034) (Table 4, Figure 1). A stepwise increase
in E-selectin was also observed when adding H.
pylori IgA seropositivity to Chlamydia LPS IgA
seropositivity, but no statistically signiﬁcant
Table 2 Number (%) of Chlamydia
pneumoniae or Helicobacter pylori IgA-
and IgG-seropositive individuals
among the CHD patients and the
individually matched healthy con-
trols, with two different serological
methods for detection of Chlamydia
antibodies
CHD
patients, n (%)
Healthy
controls, n (%) P
C. pn MIF IgA 32 63 (32.6) 62 (32.1) 0.913
C. LPS rELISA IgA 50 79 (40.9) 62 (32.1) 0.072
C. pn MIF IgG 64 119 (61.7) 108 (56.0) 0.255
C. LPS rELISA IgG 100 119 (61.7) 97 (50.3) 0.024
H. pylori IgA 20U/ml 107 (55.4) 87 (45.1) 0.042
H. pylori IgG 20U/ml 86 (44.6) 77 (39.9) 0.354
Cross tabs with Pearson w2 test was used to compare the number of seropositives
between the study groups. P values are two-tailed and refer to differences
between the groups.
C.pn: Chlamydia pneumoniae.
C.LPS: Chlamydia lipopolysaccharide.
Table 3 Levels of soluble CAMs in relation to Chlamydia
serology in patients with CHD
sICAM-1 sVCAM-1 E-selectin
MIF IgA 32 321 (126) 608 (250) 47.5 (20.6)
MIF IgA< 32 328 (138) 650 (183) 47.9 (22.5)
LPS IgA 50 352 (179) 657 (226) 51.5 (24.4)
LPS IgA< 50 308 (87) 622 (193) 45.1 (19.5)
MIF IgG 64 321 (110) 633 (231) 48.1 (23.2)
MIF IgG< 64 333 (166) 641 (164) 47.2 (19.6)
LPS IgG 100 318 (111) 646 (217) 47.7 (20.6)
LPS IgG< 100 337 (164) 620 (191) 47.8 (23.8)
Mean values (SD) in ng/mL are given.
P< 0.05 for titres of LPS IgA 50 as compared with <50,
using independent t-test.
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differences between the groups were obtained.
The mean sVCAM-1 level in CHD patients was
not signiﬁcantly altered by Chlamydia LPS IgA
seropositivity, but higher levels of sVCAM-1 were
observed in CHD patients with IgA seropositivity
to both agents when compared to the individuals
with Chlamydia LPS IgA seropositivity alone (P¼
0.018). In the healthy individuals, single or double
seropositivity did not inﬂuence the level of sCAMs
(Figure 1).
DISCUSSION
In the present study we found a signiﬁcant posi-
tive association between Chlamydia IgA LPS ser-
opositivity and the levels of sICAM-1 and E-
selectin in patients with coronary heart disease.
H. pylori antibodies alone were not associated with
any increase in soluble cell adhesion molecules,
but we observed elevated levels of sVCAM-1 in
patients who were IgA positive to both micro-
organisms compared to those that were only Chla-
mydia IgA positive. In the healthy individuals
there was no association between serology and
the levels of sCAMs.
To our knowledge, it has not previously been
shown that seropositivity to C. pneumoniae in CHD
patients is associated with elevated endothelial
inﬂammatory markers. These observations may
indicate that C. pneumoniae is more than an inno-
cent bystander in the vessel wall and that C.
pneumoniae, and possibly also H. pylori, may play
active roles in vascular inﬂammation and the
development of atherosclerosis in humans. How-
ever, to justify this hypothesis, these results need
to be conﬁrmed by others.
Serology is a diagnostic tool with obvious lim-
itations. It does not discriminate properly between
a chronic, persistent infection and a past and cured
one. Serology measures the humoral immunolo-
gical response, and enables us to conclude that the
seropositive individual has once been infected
with the microbe. The antibody measurements
cannot indicate the outcome of the initial infec-
tion, whether the microbe was killed or if a per-
sistent, low-grade infection still exists. The high
prevalence of Chlamydia antibodies, even in the
healthy population, and the relatively small differ-
ences between the study groups indicate that this
infection is fairly common and does not in general
n sICAM-1 sVCAM-1 E-selectin
1: LPS IgA/Hel IgA 55 300 (85) 634 (220) 45.4 (19.8)
2: LPS IgAþ/Hel IgA 31 321 (94) 582 (184) 51.0 (26.6)
3: LPS IgAþ/Hel IgAþ 48 372 (215) 705 (239) 51.9 (23.2)
Mean values (SD) in ng/mL, n¼number of patients in three combinations).
LPS IgA: Chlamydia lipopolysaccharide IgA; Hel IgA: Helicobacter pylori IgA.
Independent t-test was used to compare levels of sCAMs between the subgroups
based upon combined Chlamydia LPS and H. pylori serological status.
 P< 0.05 when compared to combination 1.
P< 0.05 when compared to combination 2.
Table 4 Levels of soluble CAMs in
CHD patients according to their
Chlamydia LPS IgA and Helicobacter
IgA status
Figure 1 Mean levels of sICAM-1, sVCAM-1 and E-selectin in the CHD patients and their matching healthy controls
according to Chlamydia LPS IgA and Helicobacter IgA status. –/–, Chlamydia LPS IgA negative, Helicobacter IgA negative;
þ/–, Chlamydia LPS IgA positive, Helicobacter IgA negative; þ/þ, Chlamydia LPS IgA positive, Helicobacter IgA positive;
solid bars, CHD patients; stippled bars, matched healthy controls.
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lead to symptomatic atherosclerotic disease. Better
tools are needed to differentiate those people with
ongoing, low-grade infection from the ones with
simply a serological marker of past and cured
disease. It remains to be shown if future micro-
biological or immunological methods reveal
greater differences in soluble inﬂammatory mar-
kers between positive and negative individuals
than those revealed in the present study, based
upon serology.
The association between seropositivity and ele-
vated levels of sCAMs was observed only in CHD
patients and not in the healthy controls, indicating
that the raised levels of sCAMs were not asso-
ciated with the infection per se. Higher levels of
sCAMs in the Chlamydia LPS IgA-positive CHD
patients might reﬂect that Chlamydia LPS contri-
butes to the endothelial inﬂammatory response in
patients with atherosclerotic disease. Whether this
is a cause or a result of their coronary athero-
sclerosis, is not possible to assess from the present
results.
The association between C. pneumoniae antibo-
dies and sCAMs was observed only with IgA. It
has been suggested that a high IgA titre reﬂects
chronic infectious activity better than IgG does
[27], but this is still controversial [25]. The fact
that IgG seropositivity is generally more prevalent
than IgA might, however, indicate that IgG more
than IgA is a marker of prior infection.
Only Chlamydia LPS IgA measured by rELISA
was associated with elevated sCAMs in the pre-
sent study.An obvious difference betweenMedac’s
rELISA and Labsystems MIF, is that the MIF tech-
nique detects antibodies that are speciﬁc for C.
pneumoniaewhile the Chlamydia LPS antibodies are
common for C. pneumoniae, C. trachomatis and C.
psittaci. To exclude C. trachomatis as the antigen
source of human Chlamydia LPS antibody produc-
tion, we analyzed the LPS-positive sera for C.
trachomatis-speciﬁc major outer membrane protein
(MOMP) antibodies. C. psittaci is probably far less
prevalent than the other two Chlamydia species
[28,29] and less likely to be the inductor of the
immune response in these patients.
No association between C. trachomatis-speciﬁc
antibodies and sCAMs was found, making it less
probable that the differences in sCAMs observed
with Chlamydia LPS seropositivity was caused by
this agent. Besides, C. pneumoniae is the only Chla-
mydia species that has been demonstrated within
the lesions in the arterial wall, and is therefore
more likely than the other Chlamydia species to
induce a vascular endothelial inﬂammatory
response.
It was not possible to investigate the sensitivity
and the speciﬁcity of the two tests included in this
study, because the deﬁnition of ‘true positives’
cannot be assessed in patients without clinical
evidence of an overt infection, and biopsy material
was not available. Other investigators, however,
have compared the sensitivity of the MIF test with
isolation of C. pneumoniae in cell culture or detec-
tion with polymerase chain reaction. Good agree-
ment, as well as low detection rates, have been
reported in different patient groups [30]. Even
though the MIF test is regarded as species-speciﬁc,
both genus [30,31] and species cross-reactivity [32]
have been reported. Nevertheless, the MIF test has
generally been regarded as the reference standard
internationally.
The antigen used in the genus-speciﬁc Chlamy-
dia LPS rELISA test is a recombinant LPS contain-
ing two Chlamydia-speciﬁc epitopes and two
epitopes which are shared between Chlamydial
LPS and the LPS in Salmonella minnesota RE-che-
motype, an enterobacterial plasmid-transformed
laboratorymutant [33–35]. The RE-chemotype LPS
is shown not to cross-react with the wild-type
enterobacterial LPS [34,35]. Persson and Haidl
demonstrated a 100% sensitivity and 99% speciﬁ-
city of Medac’s Chlamydia LPS rELISA when com-
pared with MIF in patients with atypical
pneumonia [30]. However, comparative results
between the different serological methods, and
also between the rELISA test and isolation in cell
culture, differ in the literature [24,36]. In the study
of Peerson and Haidl possible cross-reactions
between C. pneumoniae and Mycoplasma pneumo-
niae were also demonstrated with both methods,
but at a very low rate [30]. These data show that
even if the probability of cross-reactivity to other
bacteria is less than with earlier tests, it cannot be
completely ruled out with the methods used in the
present study.
Recently, the surface structure of C. pneumoniae
elementary bodies, the infectious forms of the
microbe, has been characterized. C. pneumoniae
is shown to express LPS aswell asMOMP epitopes
on the surface [37]. If infectious elementary bodies
are found in the circulation or are liberated from
infected cells in the atheroma, it is likely that the
surface exposed components act as major antigens
stimulating the immune response [38]. Free LPS
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may also be present as the result of LPS release
from the elementary bodies [39] and contribute to
the immune stimulation.
Our results do not support the hypothesis that
H. pylori has an independent role inducing vascu-
lar inﬂammation. On the other hand, CHDpatients
with IgA antibodies to this microbe in addition to
Chlamydia LPS IgA antibodies, had the highest
levels of sCAMs (Figure 1). In CHD patients with
an increased endothelial inﬂammatory response, a
systemic inﬂuence from H. pylori infection might
tend to aggravate it. These ﬁndings agree with
those from the study by Anderson et al. [40],
demonstrating that seropositivity to both C. pneu-
moniae and H. pylori, but not to one agent alone,
predicted higher levels of C-reactive protein and
increased risk for CHD and myocardial infarction.
In general, the design of the present study can
only point to associations and therefore only
allows assumptions regarding causality.
In conclusion, increased titres of Chlamydia LPS
IgA antibodies were associated with statistically
signiﬁcantly elevated levels of sICAM-1 and E-
selectin in CHD patients, but not in healthy indi-
viduals. This may indicate that C. pneumoniae or
the immunological response to the microbe induce
vascular inﬂammation.Moreover, inCHDpatients,
H. pylori IgA antibodies, when present in addition
to Chlamydia LPS IgA, seemed to predict an even
larger increase in sICAM-1 and sVCAM-1, indica-
tive of aggravation of the endothelial inﬂamma-
tory response.
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